About APMOSS 2027
The Asian Society for Poly-Endocrine Metabolic Ovarian Syndrome convenes its first annual congress to align PMOS care across Asia.
Why an Asian paradigm
Poly-Endocrine Metabolic Ovarian Syndrome (PMOS) is the primary aetiology of anovulatory infertility, severe metabolic disruption and accelerated cardiometabolic disease across the Asia-Pacific region.
Compared with Western cohorts, Asian women show marked visceral adiposity at lower BMI thresholds, pronounced hyperinsulinaemia, altered follicular responsiveness and heightened susceptibility to OHSS.
- Harmonise diagnostic thresholds using age-adjusted AMH nomograms across Asian phenotypes
- Optimise non-ART ovulation induction: letrozole, metformin, surgical diathermy
- Implement personalised stimulation (follitropin delta, HP-hMG) and zero-OHSS algorithms
- The 2027 Asian Clinical Consensus on Infertility & ART via modified Delphi voting
- A 12-nation longitudinal Asian PMOS Registry
- Consensus statement in an indexed Q1 REI journal
Asian PMOS Society, in official collaboration with the REI Committee of AOFOG and supported by POGI as host society.
Organizing Committee
Names and roles to be announced.
Scientific Committee
Names and roles to be announced.
Consensus Steering Committee
Leads the draft guidelines presented on Sunday. Members to be announced.
